Study Summary
This trial is testing a new drug, NTX-1088, to see if it is safe and effective in treating people with advanced solid cancers. The trial will have two parts, with the first part testing different doses of the drug to see what is safe, and the second part testing the drug in combination with another drug, pembrolizumab, to see if it is effective.
- Locally Advanced Solid Tumors
- Cancer
- Solid Tumors
- Metastatic Cancer
- Advanced Solid Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 5 Secondary · Reporting Duration: Day 1 of dosing through 90 days after the last dose.
Trial Safety
Safety Progress
Side Effects for
Trial Design
4 Treatment Groups
Part 2 - Dose Expansion (Combination Therapy)
1 of 4
Part 1 - Dose Escalation Phase (Monotherapy)
1 of 4
Part 2 - Dose Expansion (Monotherapy)
1 of 4
Part 1 - Dose Escalation Phase (Combination Therapy)
1 of 4
Experimental Treatment
90 Total Participants · 4 Treatment Groups
Primary Treatment: NTX-1088 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 13 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are applications being accepted for this trial presently?
"As gleaned from clinicaltrials.gov, this trial is no longer accepting patients; the initial post date was June 1st 2022 while its last edit occurred on May 12th 2022. Nonetheless, there are 3,700 other trials actively recruiting right now." - Anonymous Online Contributor
What degree of safety has been demonstrated for NTX-1088?
"Our experts at Power have calculated that NTX-1088's safety is rated a 1 on the scale of 1 to 3 due to it being in its initial stage of clinical trial testing and having limited supporting evidence." - Anonymous Online Contributor
What are the anticipated results of this research project?
"The primary endpoint of this investigation, which is measured over a period extending from the Screening to 30 days after last dose-Finding, concerns Dose. The secondary objectives encompass Objective Response Rate (ORR) according to RECIST v1.1., Duration of Response (DoR), and Progression Free Survival (PFS). DoR refers to the time between when criteria for PR or CR are first met until measurement criteria for progressive disease have been fulfilled, while PFS evaluates the timeline starting at initiation of study therapy up till either progression or death." - Anonymous Online Contributor